Pay in 4 interest-free payments of $6.29 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Everyone has different dietary needs
Rather than a once-weekly drug like Ozempic, this is a daily drug that is, again, used for either diabetes or obesity
Although MTHFR does not directly cause B12 deficiency, research suggests that people with the MTFHR C677T mutation have a significantly higher risk of deficiency
Specific results from treatments like Tirzepatide and Semaglutide can vary: Tirzepatide: Average weight loss is 20.9% by 36 weeks and 25.3% by 88 weeks, leveraging GLP-1 and GIP receptor agonists
These medications mimic incretin hormones to slow gastric emptying, reduce appetite, and enhance insulin secretion
Given the severity of obesity in mutation carriers, equitable access to obesity medications should be a priority for this group, in whom diet and exercise interventions are unlikely to be effective
US$ 29.34
US$ 23.40
US$ 28.94
US$ 25.93
US$ 25.60
